# Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

> **NCT00734864** · PHASE1 · WITHDRAWN · sponsor: **Annick Desjardins**

## Conditions studied

- Glioblastoma Multiforme
- Gliosarcoma
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Glioma

## Interventions

- **DRUG:** enzyme-inducing anti-epileptic drugs
- **DRUG:** enzyme-inducing anti-epileptic drugs

## Key facts

- **NCT ID:** NCT00734864
- **Lead sponsor:** Annick Desjardins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-06
- **Primary completion:** 2010-06
- **Final completion:** 2012-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.
- **Last updated:** 2012-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734864, "Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00734864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*